2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.Peer-Reviewed Original ResearchBreast cancerEIA patientsDermatology referralsOnset of alopeciaRetrospective cohort studyMetastatic breast cancerRisk of alopeciaCyclin-dependent kinase 4Endocrine monotherapyOral minoxidilEndocrine therapyClinical improvementCohort studyRetrospective cohortFemale patientsTherapeutic optionsCombination therapyGrade severityTherapeutic responseFavorable outcomeAndrogenetic alopeciaDean scaleCDK4/6iPatientsSignificant improvement
2021
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Davies M, Russo A. Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. Current Cancer Research 2021, 139-173. DOI: 10.1007/978-3-030-74028-3_7.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune related adverse eventsImmune-related adverse eventsRelated adverse eventsCheckpoint inhibitorsAdverse eventsAnti-PD-1/PD-L1Life-threatening organ failureOrgan systemsManagement of toxicitiesCourse of treatmentDegree of severityPD-L1Organ failureGrade severityRisk factorsClinical practiceImmune systemCancer subtypesModern oncologyCancer treatmentOrgan pathophysiologyBasis of toxicityPresent signsToxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply